Bruce Cohen is a Venture Partner with Xeraya Capital and CEO of Anergent Pharmaceuticals. He was the founding President and CEO of Acacia Biosciences, Cellerant Therapeutics and VitaPath Genetics. He also served as CFO at GeneSoft Pharmaceuticals. Previously, Bruce held senior positions in business development and marketing at Sequus Pharmaceuticals and at Baxter. As an independent consultant, Bruce has taken on interim management roles in public and private biotech companies, focusing on merger transactions and restructurings. Bruce holds a BA and an MA from Tufts University, as well as an MBA with distinction from Harvard Business School.